• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

FGFR2 Gene Record

  • Summary
  • Interactions
  • Claims
  • FGFR2 2263 Druggable GenomeClinically Actionable

    Alternate Names:

    2263
    FIBROBLAST GROWTH FACTOR RECEPTOR 2
    FGFR2
    BBDS
    BEK
    BFR-1
    CD332
    CEK3
    CFD1
    ECT1
    JWS
    K-SAM
    KGFR
    TK14
    TK25
    176943
    3689
    ENSG00000066468
    OTTHUMG00000019175
    FGFR-2
    KSAM
    CD_antigen=CD332
    Keratinocyte growth factor receptor
    FGFR2_HUMAN
    P21802
    22
    FIBROBLAST GROWTH FACTOR RECEPTOR 2 PRECURSOR (EC 2.7.1.112) (FGFR-2) (KERATINOCYTE GROWTH FACTOR RECEPTOR 2). [SOURCE:UNIPROT/SWISSPROT;ACC:P21802]
    FGFR1-3
    PA28128
    T58454

    Gene Info:

    CancerCommons Reported Gene Name FGFRs
    Human Readable Name DRUGGABLE GENOME
    Transmembrane Helix Count 1
    Target Main Class Receptors
    Target Subclass Kinase
    Target Subclass FGFR
    Target Class Receptors
    Target Subclass EC:2.7.10.1
    Initial Gene Query FGFR2
    Counted Citations from 1950-2000 944
    Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain
    Human Readable Name KINASE
    Uniprot Status Swiss-Prot
    Interpro Acc IPR001245
    Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom
    Uniprot Evidence 1: Evidence at protein level
    Interpro Type Domain
    Gene Biotype PROTEIN_CODING
    (24 More Sources)

    Gene Categories: Category Details

    CELL SURFACE
    KINASE
    TYROSINE KINASE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE

    Publications:

    Mazzaferro V et al., 2019, Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma., Br J Cancer
    Hall TG et al., 2016, Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation., PLoS One
    Martignetti et al., 2014, Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA., Neoplasia
    Konecny et al., 2013, Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells., Mol. Cancer Ther.
    Packer et al., 2017, PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers., Mol. Cancer Ther.
    Tanizaki et al., 2015, Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2., Cancer Res.
    Arai et al., 2014, Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma., Hepatology
    Künstlinger et al., 2015, FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro., Oncotarget
    Liu et al., 2017, c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors., Clin. Cancer Res.
    Goyal et al., 2017, Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma., Cancer Discov
    Nogova et al., 2017, Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study., J. Clin. Oncol.
    Javle M et al., 2018, Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma., J Clin Oncol
    Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.
    Guagnano et al., 2012, FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor., Cancer Discov
    Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
    Dutt et al., 2008, Drug-sensitive FGFR2 mutations in endometrial carcinoma., Proc. Natl. Acad. Sci. U.S.A.
    Byron et al., 2013, The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors., Neoplasia
    André et al., 2013, Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer., Clin. Cancer Res.
    Eritja N et al., 2014, Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells., Mol Cancer Ther
    Tabernero et al., 2015, Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors., J. Clin. Oncol.
    Perera et al., 2017, Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor., Mol. Cancer Ther.
    Loriot Y et al., 2019, Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma., N Engl J Med
    Nishina T et al., 2018, Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors., Invest New Drugs
    Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.
    Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet
    Manchado et al., 2016, A combinatorial strategy for treating KRAS-mutant lung cancer., Nature
    Matsui et al., 2008, E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition., Int. J. Cancer
    Harding et al., 2013, Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer., Sci Transl Med
    Secrier et al., 2016, Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance., Nat. Genet.
    Abou-Alfa GK et al., 2020, Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study., Lancet Oncol
    Liu PCC et al., 2020, INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models., PLoS One
    Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
    Koole et al., 2016, FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma., Clin. Cancer Res.
    Eichholz et al., 2010, Anti-angiogenesis therapies: their potential in cancer management., Onco Targets Ther
    Patrie et al., 1995, Conservation of ligand specificity between the mammalian and amphibian fibroblast growth factor receptors., J. Biol. Chem.
    Zhu et al., 2007, Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells., Am. J. Pathol.
    Beaven et al., 2007, Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant., Drugs Today
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Radtke et al., 2005, Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support., J Oncol Pharm Pract
    Cardoso et al., 1997, FGF-1 and FGF-7 induce distinct patterns of growth and differentiation in embryonic lung epithelium., Dev. Dyn.
    Huang et al., 2006, Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells., J. Steroid Biochem. Mol. Biol.
    Berman et al., 1999, Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor., J. Biol. Chem.
    Gozgit et al., 2013, Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models., Cancer Chemother. Pharmacol.
    Kim et al., 2016, Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations., Cancer Biol. Ther.
    Borad et al., 2014, Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma., PLoS Genet.
    Grünewald S et al., 2019, Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models., Int J Cancer
    Goyal L et al., 2019, TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma., Cancer Discov
    Nakanishi et al., 2015, ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor., Mol. Cancer Ther.
    Yoon et al., 2009, Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells., Mol. Cancer Ther.
    Wang et al., 2016, Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report., Medicine (Baltimore)
    Liao et al., 2013, Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma., Cancer Res.
    Jo et al., 2015, Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity., Mol. Cancer Ther.
    Watanabe Miyano et al., 2016, E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models., Mol. Cancer Ther.
  • PALIFERMIN   FGFR2

    Interaction Score: 2.42

    Interaction Types & Directionality:
    agonist (activating)
    binder

    Interaction Info:
    Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance
    Novel drug target Established target
    Mechanism of Interaction Fibroblast growth factor receptor 2 agonist

    PMIDs:
    7499435 17456767 17728847 11752352 16390600 9056643 16854582 10593896


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • FUTIBATINIB   FGFR2

    Interaction Score: 1.82

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type biliary tract cancer
    Response Type predicted – sensitive
    Approval Status Phase I

    PMIDs:
    31109923


    Sources:
    JAX-CKB CIViC

  • PEMIGATINIB   FGFR2

    Interaction Score: 1.62

    Interaction Types & Directionality:
    activator (activating)
    inhibitor (inhibitory)

    Interaction Info:
    Response Type sensitive
    Indication/Tumor Type Advanced Solid Tumor
    Approval Status Preclinical - Cell culture

    PMIDs:
    32203698 32315352


    Sources:
    JAX-CKB CIViC

  • ERDAFITINIB   FGFR2

    Interaction Score: 1.62

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type urinary system cancer
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    26324363 28341788 31340094 28965185


    Sources:
    JAX-CKB CIViC PharmGKB OncoKB

  • E-7090   FGFR2

    Interaction Score: 1.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    18552176 27535969


    Sources:
    JAX-CKB

  • DERAZANTINIB   FGFR2

    Interaction Score: 1.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Fibroblast growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    30420614 27627808


    Sources:
    ChemblInteractions CIViC

  • INFIGRATINIB   FGFR2

    Interaction Score: 0.99

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Direct Interaction yes
    Mechanism of Interaction Fibroblast growth factor receptor inhibitor

    PMIDs:
    24563622 23443805 28119489 26048680 24122810 26036639 27401245 28034880 27870574 29182496


    Sources:
    TALC MyCancerGenome JAX-CKB ChemblInteractions CIViC CancerCommons MyCancerGenomeClinicalTrial OncoKB

  • ROGARATINIB   FGFR2

    Interaction Score: 0.97

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type predicted – sensitive
    Approval Status Phase I

    PMIDs:
    30807645


    Sources:
    JAX-CKB ChemblInteractions CIViC

  • TRABECTEDIN   FGFR2

    Interaction Score: 0.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Dovitinib + Trabectedin
    Indication/Tumor Type myxoid liposarcoma
    Response Type sensitive

    PMIDs:
    26036639


    Sources:
    JAX-CKB

  • PONATINIB   FGFR2

    Interaction Score: 0.77

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Clinical Status preclinical
    Pathway activation
    Variant Effect gain-of-function

    PMIDs:
    26619011 23002168 22238366 18552176 23908597 23468082 26048680 26574622 24550739


    Sources:
    TALC MyCancerGenome JAX-CKB DoCM CIViC

  • FP-1039   FGFR2

    Interaction Score: 0.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft
    Response Type sensitive

    PMIDs:
    23536011


    Sources:
    TdgClinicalTrial JAX-CKB

  • LY-2874455   FGFR2

    Interaction Score: 0.61

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Fibroblast growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • TRAFERMIN   FGFR2

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name trafermin, fibro/
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TTD

  • BRIVANIB   FGFR2

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Response Type decreased response
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive

    PMIDs:
    22238366 20124951


    Sources:
    JAX-CKB ChemblInteractions PharmGKB

  • PHA-665752   FGFR2

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type hepatocellular carcinoma
    Response Type no benefit
    Approval Status Preclinical - Cell culture

    PMIDs:
    26351320


    Sources:
    JAX-CKB

  • NINTEDANIB   FGFR2

    Interaction Score: 0.46

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name BIBF-1120,Vargatef
    Novel drug target Established target
    Notes

    PMIDs:
    18559524 22238366 31016670


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB

  • DEBIO-1347   FGFR2

    Interaction Score: 0.4

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    OncoKB

  • RO-4987655   FGFR2

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal adenocarcinoma
    Response Type decreased response
    Approval Status Preclinical - Cell culture

    PMIDs:
    26438159


    Sources:
    JAX-CKB

  • AZD-4547   FGFR2

    Interaction Score: 0.3

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Fibroblast growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DOVITINIB   FGFR2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name dovitinib, TKI-258, CHIR-258
    Variant Effect gain-of-function

    PMIDs:
    26619011 23002168 22238366 18552176 23908597 23443805 26036639 23658459 24448819


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB DoCM CIViC

  • LUCITANIB   FGFR2

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Fibroblast growth factor receptor 2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • AEE-788   FGFR2

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • LENVATINIB   FGFR2

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    17943726


    Sources:
    TALC

  • FULVESTRANT   FGFR2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24448819


    Sources:
    CIViC

  • BRIVANIB ALANINATE   FGFR2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Fibroblast growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CP-459632   FGFR2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Fibroblast growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • XL-228   FGFR2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome

  • RABEPRAZOLE SODIUM   FGFR2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome TTD

  • NINTEDANIB ESYLATE   FGFR2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Fibroblast growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ORANTINIB   FGFR2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Fibroblast growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • MUPARFOSTAT   FGFR2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name Muparfostat
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • PAZOPANIB   FGFR2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Clinical Status case report
    Pathway activation
    Variant Effect gain-of-function

    PMIDs:
    24550739 23786770


    Sources:
    DoCM CIViC

  • XL-999   FGFR2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Fibroblast growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • SELUMETINIB   FGFR2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type decreased response
    Indication/Tumor Type endometrial carcinoma
    Approval Status Preclinical - Cell culture

    PMIDs:
    26438159 19755509


    Sources:
    JAX-CKB

  • THALIDOMIDE   FGFR2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Thalomid
    Novel drug target Established target

    PMIDs:
    20616958


    Sources:
    TdgClinicalTrial TEND

  • ENMD-2076   FGFR2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name ENMD-2076
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ClearityFoundationClinicalTrial

  • MK-2461   FGFR2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • BUPARLISIB   FGFR2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BGJ398 + BKM120
    Indication/Tumor Type endometrial cancer
    Response Type sensitive

    PMIDs:
    28119489


    Sources:
    JAX-CKB

  • LAPATINIB   FGFR2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type sensitive

    PMIDs:
    27595477


    Sources:
    JAX-CKB

  • REGORAFENIB   FGFR2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Fibroblast growth factor receptor 2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions MyCancerGenomeClinicalTrial

  • MASITINIB   FGFR2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • PICTILISIB   FGFR2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type sensitive

    PMIDs:
    28119489


    Sources:
    JAX-CKB

  • TG100-801   FGFR2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Fibroblast growth factor receptor 2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ALPELISIB   FGFR2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type sensitive

    PMIDs:
    28119489


    Sources:
    JAX-CKB

  • SUNITINIB   FGFR2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + Sunitinib
    Indication/Tumor Type olfactory neuroblastoma
    Response Type sensitive

    PMIDs:
    27149458


    Sources:
    JAX-CKB

  • TRAMETINIB   FGFR2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type no benefit

    PMIDs:
    27338794


    Sources:
    JAX-CKB

  • CETUXIMAB   FGFR2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + Sunitinib
    Indication/Tumor Type olfactory neuroblastoma
    Response Type sensitive

    PMIDs:
    27149458


    Sources:
    JAX-CKB

  • CEDIRANIB   FGFR2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type decreased response
    Indication/Tumor Type Advanced Solid Tumor
    Indication/Tumor Type endometrial cancer

    PMIDs:
    22238366


    Sources:
    JAX-CKB

  • ENMD-981693   FGFR2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Fibroblast growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • GEFITINIB   FGFR2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type sensitive

    PMIDs:
    26936917


    Sources:
    JAX-CKB

  • RG-1530   FGFR2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Fibroblast growth factor receptor 2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • Ensembl: ENSG00000066468

    • Version: 101_38

    Alternate Names:
    FGFR2 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000066468

    • Version: 26-July-2011

    Alternate Names:
    FGFR2 Display Id
    ENSG00000066468 Ensembl Gene Id
    FIBROBLAST GROWTH FACTOR RECEPTOR 2 PRECURSOR (EC 2.7.1.112) (FGFR-2) (KERATINOCYTE GROWTH FACTOR RECEPTOR 2). [SOURCE:UNIPROT/SWISSPROT;ACC:P21802] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HopkinsGroom: P21802

    • Version: 11-September-2012

    Alternate Names:
    ENSG00000066468 Ensembl Gene Id
    FGFR2 Uniprot Gene Name
    P21802 Uniprot Accession

    Gene Info:
    Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain
    Human Readable Name KINASE
    Uniprot Status Swiss-Prot

    Gene Categories:
    KINASE, DRUGGABLE GENOME

    Publications:

  • TEND: P21802

    • Version: 01-August-2011

    Alternate Names:
    ENSG00000066468 Ensembl Gene Id
    P21802 Uniprot Accession
    2263 Entrez Gene Id

    Gene Info:
    Transmembrane Helix Count 1
    Target Main Class Receptors
    Target Subclass Kinase

    Publications:

  • CancerCommons: FGFR2

    • Version: 25-July-2013

    Alternate Names:
    2263 Entrez Gene ID

    Gene Info:
    CancerCommons Reported Gene Name FGFRs

    Publications:

  • TdgClinicalTrial: P21802

    • Version: January-2014

    Alternate Names:
    FGFR2 Gene Symbol

    Gene Info:
    Target Class Receptors
    Target Subclass EC:2.7.10.1

    Publications:

  • BaderLabGenes: FGFR2

    • Version: February-2014

    Alternate Names:
    2263 Entrez Gene ID

    Gene Info:
    Initial Gene Query FGFR2
    Counted Citations from 1950-2000 944

    Gene Categories:
    KINASE

    Publications:

  • JAX-CKB: FGFR2

    • Version: 27-September-2017

    Alternate Names:
    2263 CKB Entrez Id
    FGFR2 CKB Gene Synonym
    BBDS CKB Gene Synonym

    Gene Info:

    Publications:
    Liu et al., 2017, c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors., Clin. Cancer Res.
    Konecny et al., 2013, Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells., Mol. Cancer Ther.
    Arai et al., 2014, Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma., Hepatology

  • PharmGKB: FGFR2

    • Version: 18-August-2020

    Alternate Names:
    PA28128 PharmGKB ID

    Gene Info:

    Publications:
    Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics

  • CIViC: FGFR2

    • Version: 14-September-2020

    Alternate Names:
    2263 Entrez Gene ID
    22 CIViC Gene ID

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:
    Liao et al., 2013, Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma., Cancer Res.
    Borad et al., 2014, Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma., PLoS Genet.
    Eritja N et al., 2014, Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells., Mol Cancer Ther

  • DoCM: FGFR2

    • Version: 27-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
    Greulich et al., 2011, Targeting mutant fibroblast growth factor receptors in cancer., Trends Mol Med
    Dutt et al., 2008, Drug-sensitive FGFR2 mutations in endometrial carcinoma., Proc. Natl. Acad. Sci. U.S.A.

  • TALC: FGFR2

    • Version: 12-May-2016

    Alternate Names:
    FGFR2 Gene Symbol

    Gene Info:

    Publications:

  • MyCancerGenome: FGFR2

    • Version: 20-Jun-2017

    Alternate Names:
    2263 Entrez Gene Id
    FGFR2 MyCancerGenome Gene Symbol
    FGFR1-3 MyCancerGenome Reported Gene Name

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000066468

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000066468 Gene Symbol
    FGFR2 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TALC: FGFR-2

    • Version: 12-May-2016

    Alternate Names:
    FGFR-2 Gene Symbol

    Gene Info:

    Publications:

  • ChemblInteractions: BEK

    • Version: chembl_23

    Alternate Names:
    KGFR GENE_SYMBOL
    KSAM GENE_SYMBOL
    FGFR2 GENE_SYMBOL

    Gene Info:

    Publications:

  • OncoKB: FGFR2

    • Version: 23-July-2020

    Alternate Names:
    2263 OncoKB Entrez Id
    BBDS OncoKB Gene Synonym
    BFR-1 OncoKB Gene Synonym

    Gene Info:

    Publications:

  • GO: FGFR2

    • Version: 01-February-2022

    Alternate Names:
    BEK GO Gene Synonym
    KGFR GO Gene Synonym
    KSAM GO Gene Synonym

    Gene Info:

    Gene Categories:
    CELL SURFACE, TYROSINE KINASE

    Publications:

  • Tempus: FGFR2

    • Version: 11-November-2018

    Alternate Names:
    FGFR2 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • dGene: FGFR2

    • Version: 27-Jun-2013

    Alternate Names:
    2263 Gene ID
    BBDS dGene Synonym
    BEK dGene Synonym

    Gene Info:

    Gene Categories:
    KINASE, TYROSINE KINASE

    Publications:

  • TTD: Fibroblast growth factor receptor 2

    • Version: 2020.06.01

    Alternate Names:
    FGFR2 TTD Gene Abbreviation
    T58454 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: FGFR2

    • Version: 01-February-2022

    Alternate Names:
    Fibroblast growth factor receptor 2 Gene Name
    P21802 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE

    Publications:

  • MskImpact: FGFR2

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • ClearityFoundationClinicalTrial: FGFR2

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • MyCancerGenomeClinicalTrial: FGFR2

    • Version: 30-February-2014

    Alternate Names:

    Gene Info:

    Publications:

  • FoundationOneGenes: FGFR2

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: FGFR2

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • Oncomine: FGFR2

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21